Recent News
10 Biggest Pharmaceutical Settlements
As consumers, we trust that the pharmaceuticals we take are safe and effective. Unfortunately, that is not always the case. Throughout the course of history, many large pharmaceutical companies have reached substantial settlements with individuals and their families after some pharmaceuticals were found to have harmful and unforeseen side effects. Here, the pharmaceutical liability attorneys…
Updates on Allergan Breast Implants Class Claim
In July 2019, pharmaceutical manufacturer Allergan ordered a recall of its BIOCELL textured breast implants after reports that the implants were linked to a serious cancer affecting hundreds of patients. Here, the pharmaceutical liability attorneys at Peter Angelos Law discuss recent updates to this serious event as well as your legal options if you have…
Johnson & Johnson Elmiron Lawsuit Update
In 2020, several lawsuits were filed against Johnson & Johnson and Janssen Pharmaceuticals claiming that Elmiron–a drug prescribed to treat painful bladder syndrome–caused them to suffer severe vision complications such as retinal damage and macular degeneration. Here, the pharmaceutical liability attorneys at Peter Angelos Law provide an update on the lawsuits. Elmiron, a drug prescribed…
Mercury-Containing Dental Amalgam May Have Harmful Health Effects to High-Risk Groups
On September 24th, 2020, the FDA published a press release issuing updated recommendations regarding the potential risks of mercury-containing dental amalgam fillings to high-risk groups. The FDA is issuing these updates as a response to certain risks surrounding the dental fillings that may predominantly impact certain high-risk groups. Dental Amalgam is a Substance Used…
FDA News Release: Opdivo and Yervoy Combination Approved to Treat Mesothelioma
For the first time in 16 years, a drug combination and FDA-approved systemic therapy has been approved to treat malignant pleural mesothelioma that cannot be removed surgically. The first-line treatment for adults will include drug combination therapy using Opdivo (nivolumab) and Yervoy (ipilimumab) to increase the chances of patient survival. Here, the pharmaceutical liability attorneys…
Recent FDA News Release: Benzodiazepines Boxed Warning to Be Updated to Include Serious Risks
On September 23rd, the U.S. Food and Drug Administration (FDA) announced that it would be requiring “class-wide labeling changes” for psychoactive drugs that fall under the class of Benzodiazepines. The label change to the Boxed Warning will include benzos’ risks of abuse, dependence, misuse, addiction and potential withdrawal symptoms. The labeling update is a reaction…
Bladder Drug Manufacturers Face Lawsuits Over Retinal Damage Linked to Elmiron
On Wednesday, August 12th, women in two separate complaints filed suit against units of Johnson & Johnson, Bayer and Teva Pharmaceuticals USA Inc. after they developed eye damage after taking bladder medication Elmiron. Here, the pharmaceutical liability attorneys at Peter Angelos Law discuss the latest updates in Elmiron litigation and what it means for patients…
Elmiron Update: Warnings Changed to Include Risk of Eye Damage
On June 16th, 2020, the Food and Drug Administration (FDA) announced labeling changes to Elmiron, a popular anticoagulant that is commonly prescribed to treat bladder pain caused by interstitial cystitis and osteoarthritis. Here, the pharmaceutical liability attorneys at Peter Angelos Law discuss the potential dangers to consumers taking Elmiron, and how to seek legal representation…
Elmiron Linked to Vision Loss
Elmiron is a popular anticoagulant that is commonly prescribed to treat bladder pain caused by interstitial cystitis and osteoarthritis. Recently, Elmiron has been linked to the increased risk of pigmentary maculopathy and other forms of vision loss and damage. The pharmaceutical liability attorneys at Peter Angelos Law Law are actively investigating cases regarding the use…
FDA Requests Removal of Zantac From the Market Immediately
On April 1st, the Food and Drug Administration (FDA) announced its request for all prescription and over-the-counter ranitidine drugs to be removed from the market immediately. This decision was made based on an ongoing investigation of possible carcinogenic effects of the contaminant N-nitrosodimethylamine, or NDMA. Here, the pharmaceutical liability attorneys at Peter Angelos Law discuss…